Non–Small Cell Lung Cancer Coverage from Every Angle

Martin Reck, MD, PhD, on Monotherapy vs Combination Treatment for High PD-L1–Expressing NSCLC: Expert Perspective

Posted: Monday, January 1, 0001

Martin Reck, MD, PhD, of the LungenClinic, discusses the clinical implications of the KEYNOTE-598 findings on combining pembrolizumab with ipilimumab vs pembrolizumab alone to treat patients who have high PD-L1–expressing non–small cell lung cancer.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.